Table 1. Demographic and clinical characteristics of subjects

Variables	TARE (n =14)	TACE (n=13)	p-value
Age (years) Male sex	61.6±14.5 12 (85.7%)	62.8±13.9 10 (76.9%)	0.829 0.557
Etiology
HBV	13 (92.9%)	11 (84.6%)	0.496
HCV	0 (0.0%)	1 (7.7%)	0.290
nBnC	1 (7.1%)	1 (7.7%)	0.957
Hypertension	2 (14.3%)	3 (23.1%)	0.557
Diabetes mellitus	3 (21.4%)	1 (7.7%)	0.315
Chronic kidney disease	1 (7.1%)	1 (7.7%)	0.957
Ischemic heart disease	1 (7.1%)	0 (0.0%)	0.326
Cerebrovascular disease	0 (0.0%)	1 (7.7%)	0.290
COPD	1 (7.1%)	0 (0.0%)	0.326
Tumor size (cm)	7.9±1.4	7.4±2.2	0.432
Child-Pugh score	5.1±0.3	5.3±0.5	0.557
AST Level (IU/L)	42.0±29.4	38.2±18.1	0.694
ALT level (IU/L)	36.9±34.3	38.0±22.3	0.925
Total bilirubin level (mg/dL)	0.8±0.3	0.8±0.5	0.601
Serum albumin level (g/dL)	4.2±0.3	3.9±0.4	0.089
Prothrombin time (Sec)	11.0±0.9	11.3±1.3	0.537
Alkaline phosphatase (IU/L)	80.6±32.4	85.7±29.7	0.673
Blood urea nitrogen (mg/dL)	16.6±4.8	16.7±5.9	0.945
Serum creatinine (mg/dL)	0.85±0.20	0.86±0.18	0.931
White blood cell (103/μL)	15,153.1±35,422.6	3,648.8±7,135.1	0.895
Hemoglobin (g/dL)	14.0±1.4	13.2±2.5	0.317
Platelet count (103/μL)	219.6±65.9	163.7±50.4	0.021
Glucose (mg/dL)	102±18.4	110±36.1	0.442
AFP (ng/mL)	15,153.1±35,422.6	3,648.8±7,135.1	0.262
PIVKA-II (mAU/mL)	1,134.6±1,057.6	12,167.4±21,191.9	0.063

Abbreviations: AFP, Alpha-fetoprotein; COPD, Chronic obstructive pulmonary disease; HBV, Hepatitis B virus; HCV, Hepatitis C virus; nBnC, non-HBV and non-HCV; PIVKA-II, Protein induced by vitamin K absence or antagonist-II; TACE, transarterial radioembolization; TARE, transarterial chemoembolization.
Variables shown are numbers (percentages) or expressed as the mean ± standard deviation. Differences in categorical variables between groups were analyzed using the Chi-square test or Fisher’s exact test. Continuous variables were compared by Student’s t-test